Adecto Pharmaceuticals announces patent issuance for licensed cancer therapy and diagnostic technology

BOSTON, Mass. (Feb 3, 2026) - Adecto Pharmaceuticals today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the core technology licensed by the company from Tufts University. This patent protection secures the development path for Adecto’s diagnostic platform and the continued evolution of its primary therapeutic candidate.

The patented technology focuses on the composition of mouse monoclonal anti-human ADAM8 antibodies and their use in the diagnosis and treatment of aggressive cancers. The antibodies simultaneously inactivate two distinct extracellular domains of ADAM8, which are responsible for its cancer functions. In preclinical models, this dual inhibitory mechanism has been shown to be an effective approach to treat ADAM8-positive cancers. Beyond treatment, the patent protects the use of these antibodies as diagnostic tools, to help select patients who could benefit from ADAM8 inhibitory therapy.

“The issuance of this patent is a significant milestone that validates our unique approach to treating refractory cancers” said Nora Mineva, CEO and co-founder of Adecto Pharmaceuticals. “By securing these rights, we can accelerate the development of our anti-ADAM8 therapy, moving one step closer to helping patients with limited treatment options”.

About Adecto Pharmaceuticals
Adecto Pharmaceuticals is a biotechnology company specializing in the development of targeted therapies and diagnostics for ADAM8-positive cancers. Founded in 2014 by Tufts researchers, the company is dedicated to stopping primary cancer growth and metastasis.